Lixte signs exclusive patent license with NINDS and NCI for LB-100 combination therapy

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Exclusive license covers NIH IP co-developed under CRADA; field includes checkpoint inhibitors, immunotherapy, radiation.
Upfront license issue royalty $50,000; annual minimum $30,000; earned royalties 2% on net sales (floor 1%).
Benchmark payments up to $1,225,000 tied to milestones; first Phase 2 patient dosing due October 2024.
LB-100 is first-in-class PP2A inhibitor; ongoing Phase 1b/2 OCCC trial with dostarlimab and Phase 1b SCLC trial with atezolizumab.
CEO called the collaboration a significant milestone to advance LB-100 as potentiator of cancer immunotherapy.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

LIXTE BIOTECHNOLOGY HOLDINGS, INC. entered into License Agreement with National Institute of Neurological Disorders and Stroke (NINDS) and National Cancer Institute (NCI), each an institute or center of the National Institute of Health (NIH) valued at $50,000 (effective 2024-02-23).

Action: entry
Agreement: license
Counterparty: National Institute of Neurological Disorders and Stroke (NINDS) and National Cancer Institute (NCI), each an institute or center of the National Institute of Health (NIH)
Value: $50,000
Effective: 2024-02-23

Exact text from the filing

On February 23, 2024, Lixte Biotechnology Holdings, Inc. (the “Company”) entered into a Patent License Agreement (the “License Agreement”) with the National Institute of Neurological Disorders and Stroke (“NINDS”) and the National Cancer Institute (“NCI”), each an institute or center of the National Institute of Health (“NIH”).

View on SEC.gov

757 material agreements filed in the last 30 days. Browse all material agreements →

LIXTE BIOTECHNOLOGY HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001493152-24-007784

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.